What exactly is the Technosphere® Platform?

NTM Lung Disease on the Rise

Share & Print option

Release Details

MannKind Elects James S. Shannon to its Board of Directors

02/24/10
MannKind Elects James S. Shannon to its Board of Directors

VALENCIA, Calif., Feb 24, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that James S. Shannon, MD, MRCP (UK) has joined the company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior leadership positions, including serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland. The addition of Dr. Shannon brings the total number of MannKind Board members to nine.

"James brings a tremendous wealth of experience to our board of directors," said Alfred Mann, Chairman and CEO of MannKind. "His perspective as an accomplished pharmaceutical executive comes at an exciting time for MannKind Corporation as we prepare to move from development to commercialization of our lead product, AFREZZA™."

Dr. Shannon is currently the President and CEO of Cerimon Pharmaceuticals, Inc. Prior to joining Cerimon in December 2008, he held the position of Global Head of Pharma Development for Novartis AG based in Basel, Switzerland. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon held a number of significant positions in Novartis including Head of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba and Sandoz and also Head of the Cardiovascular Strategic Team. Subsequently he was appointed Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of Research and Development ultimately serving as Senior Vice-President, Clinical Development. Dr. Shannon is trained in Medicine and Cardiology. He received his undergraduate and postgraduate degrees at Queen's University of Belfast and is a Member of the Royal College of Physicians (UK).

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFREZZA™ (formerly AFRESA®), MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The other three programs are currently in Phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the market opportunities for MannKind's product candidates, that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, difficulties or delays in seeking or obtaining regulatory approval, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, the risk that commercialization partners may not be successful in their sales and marketing efforts, intellectual property matters, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2008 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

SOURCE: MannKind Corporation

MannKind Corporation
Matthew Pfeffer
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com